Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, 23538 Lübeck, Germany.
University Hospital Schleswig-Holstein, Department of Cardiology, University Heart Center Lübeck, 23538 Lübeck, Germany.
Int J Mol Sci. 2022 Jun 13;23(12):6585. doi: 10.3390/ijms23126585.
P2X receptors belong to a family of cation channel proteins, which respond to extracellular adenosine 5'-triphosphate (ATP). These receptors have gained increasing attention in basic and translational research, as they are central to a variety of important pathophysiological processes such as the modulation of cardiovascular physiology, mediation of nociception, platelet and macrophage activation, or neuronal-glial integration. While P2X1 receptor activation is long known to drive platelet aggregation, P2X7 receptor antagonists have recently been reported to inhibit platelet activation. Considering the role of both P2X receptors and platelet-mediated inflammation in neuronal diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and stroke, targeting purinergic receptors may provide a valuable novel therapeutic approach in these diseases. Therefore, the present review illuminates the role of platelets and purinergic signaling in these neurological conditions to evaluate potential translational implications.
P2X 受体属于阳离子通道蛋白家族,对细胞外三磷酸腺苷(ATP)起反应。这些受体在基础和转化研究中受到越来越多的关注,因为它们是多种重要病理生理过程的核心,如心血管生理学的调节、伤害感受的介导、血小板和巨噬细胞的激活或神经元-神经胶质的整合。虽然 P2X1 受体的激活长期以来被认为会导致血小板聚集,但最近有报道称 P2X7 受体拮抗剂可抑制血小板激活。考虑到 P2X 受体和血小板介导的炎症在多发性硬化症、阿尔茨海默病、帕金森病和中风等神经疾病中的作用,针对嘌呤能受体可能为这些疾病提供一种有价值的新的治疗方法。因此,本综述阐明了血小板和嘌呤能信号在这些神经状况中的作用,以评估潜在的转化意义。